ENTITY
stringlengths 8
8
| DEFINITION
stringlengths 3
8.47k
⌀ | ALIASES
stringlengths 2
13.6k
⌀ | NAME
stringlengths 2
1.98k
|
|---|---|---|---|
C0027022 | Conditions which cause proliferation of hemopoietically active tissue or of tissue which has embryonic hemopoietic potential. They all involve dysregulation of multipotent MYELOID PROGENITOR CELLS, most often caused by a mutation in the JAK2 PROTEIN TYROSINE KINASE. | MYELOPROLIFERATIVE DISORDER|Disorder, Myeloproliferative|Myeloproliferative neoplasms|Myeloproliferative disease, NOS|Myeloproliferative disorder|disorder myeloproliferative|Myeloproliferative Disorders|Proliferation of myeloid cells|DISORDER MYELOPROLIFERATIVE|myeloproliferative neoplasm|disorders myeloproliferative|diseases myeloproliferative|Disorders, Myeloproliferative|myeloproliferative disorders|Myeloproliferative disorder (morphologic abnormality)|Myeloproliferative disorders|myeloproliferative disorder|myeloproliferative disease|Myeloproliferative disorder (disorder)|disease myeloproliferative|Myeloproliferative disease|Myeloproliferative Disorder | Myeloproliferative disease |
C0026857 | Diseases of the muscles and their associated ligaments and other connective tissue and of the bones and cartilage viewed collectively. | Orthopedic Disorders|musculoskeletal disease|Musculoskeletal System Disorder|disease musculoskeletal|Musculoskeletal Disease|disease musculoskeletal system|Musculoskeletal disorder|Disorder of the musculoskeletal system, NOS|disorder musculoskeletal|diseases musculoskeletal|disorders musculoskeletal|Disease of the musculoskeletal system, NOS|Musculoskeletal system--Diseases|Disorder of musculoskeletal system (disorder)|disorders musculoskeletal system|musculoskeletal disorders|Musculoskeletal Disorder|disorders musculo skeletal|musculoskeletal diseases|Musculoskeletal Diseases|Disorder of Musculoskeletal System|diseases musculoskeletal system|musculoskeletal disorder|Disorder of musculoskeletal system|Orthopedic Disorder | Musculoskeletal Diseases |
C0161750 | null | Exhaustion due to excessive exertion|overexertion|Exhaustion due to excessive exertion (finding)|Overexertion | Exhaustion due to excessive exertion |
C0857121 | null | with high blood pressure|hypertensive | Hypertensive (finding) |
C0149721 | Enlargement of the LEFT VENTRICLE of the heart. This increase in ventricular mass is attributed to sustained abnormal pressure or volume loads and is a contributor to cardiovascular morbidity and mortality. | lv hypertrophy|Enlarged left ventricle|Left ventricular wall hypertrophy|Left ventricular enlargement|Hypertrophies, Left Ventricular|LVH|Ventricular Hypertrophy, Left|Ventricular Hypertrophies, Left|Left ventricle hypertrophied|Heart left ventricle hypertrophy|Hypertrophy, Left Ventricular|Cardiomegaly of left ventricle|LV hypertrophy|Left Ventricular Hypertrophies|Left ventricular hypertrophy (disorder)|VENTRICULAR HYPERTROPHY, LEFT|Left Ventricular Hypertrophy|LEFT VENTRICULAR HYPERTROPHY|LVH - Left ventricular hypertrophy|Cardiomegaly of left ventricle (disorder)|hypertrophy left ventricular|Left ventricular hypertrophy|lvh|left ventricular hypertrophy|left ventricular enlargement|LV+ - Left ventricular hypertrophy | Left Ventricular Hypertrophy |
C0205400 | null | Thickening|Increased thickness|thickening|Increased thickness (finding)|Thickness, increased|Thickened (qualifier value)|thickenings|thicken|thickened|thickens|Thickened | Thickened |
C0067385 | A methylated derivative of L-arginine that is a competitive inhibitor of nitric oxide synthase (NOS). Asymmetric dimethylarginine (ADMA) is formed when S-adenosylmethionine protein N-methyltransferases transfer methyl groups from S-adenosylmethionine to arginine. Free ADMA in plasma competes with the L-arginine for binding to the heme in NOS and inhibits nitric oxide (NO) synthesis. Decreased synthesis of NO inhibits vasodilation and leads to endothelial dysfunction. Elevated plasma levels of ADMA are seen in certain types of cancer, cardiovascular disease, hypertension, hyperlipidemia, type 2 diabetes mellitus, and increased oxidative stress. | N(G)-dimethylarginine|N,N-dimethylarginine|ADMA|N(5)-((dimethylamino)iminomethyl)-L-ornithine|Asymmetric Dimethylarginine|guanidino-N,N-dimethylarginine|N(G),N(G)-dimethylarginine|asymmetric dimethylarginine|dimethyl-L-arginine|N(G1),N(G1)-dimethylarginine | N,N-dimethylarginine |
C0021083 | Manipulation of the host's immune system in treatment of disease. It includes both active and passive immunization as well as immunosuppressive therapy to prevent graft rejection. | Immunotherapies|immunotherapy|immunotherapies|Immunologically Directed Therapy|Immunotherapy (procedure)|IMMUNOTHERAPY|Immunological therapy|Immunotherapy|Immunotherapy, NOS|Immunological care|Biological response modifier therapy, NOS|Biological response modifier therapy | Immunotherapy |
C0019693 | Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). | Infection, HTLV-III-LAV|Human immunodeficiency virus infection (disorder)|HIV disease|HTLV-III-LAV Infection|HIV - Human immunodeficiency virus infection|HIV seropositivity or positivity|Infections, HIV|T-Lymphotropic Virus Type III Infections, Human|HUMAN IMMUNODEFICIENCY VIRUS [HIV] INFECTION|DISEASES DUE TO IMMUNODEFICIENCY VIRUS|HTLV III LAV Infections|Human immunodeficiency virus infection|HTLV-III Infection|HIV infection|Infections, HTLV-III|HIV DISEASE|HTLV-III Infections|HTLV-III-LAV Infections|Human immunodeficiency virus [HIV] disease|Human immunodeficiency virus disease|hiv infection|Infection, HIV|HIV infections|T Lymphotropic Virus Type III Infections, Human|HIV Infections|Human immunodeficiency virus infection, NOS|Infection, HTLV-III|Infections, HTLV-III-LAV|HIV Infection|HTLV III Infections | HIV Infections |
C0600249 | null | Passive Immunotherapy|passive immunotherapy|Passive Immunotherapies|Immunotherapies, Passive | Immunotherapy, Passive |
C1152609 | OBSOLETE. An agent that can lyse cells. [ISBN:0198547684] | lysin activity | lysin activity |
C0023418 | A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) | Leucocythemia|Leukemia, disease (disorder)|Leucocythaemias|LEUKEMIA|leukemia types|Unspecified Leukemias|Blood (Leukemia)|Leukemia, Disease|leukaemias|Leukemia, NOS|leukemias|LEUKEMIAS|types leukemia|Leucocythemias|LEUKEMIAS, NOS|Leukaemia, NOS|Leukaemia morphology|leukaemia|LEUKEMIA, MALIGNANT|Leukemia morphology|Leukemias, General|Leukemia, disease|Leukaemia, no ICD-O subtype|all types of leukemia|Unspecified leukemia|Leukemia|Leukemia, no International Classification of Diseases for Oncology subtype|leukemias types|Leukemia NOS|Leukemia, no ICD-O subtype|leukemia|LEUKAEMIA|Leukaemia|Leukemias|Leukemia, NOS, without mention of remission|Leukaemia, NOS, without mention of remission|Leucocythaemia|Leukaemia, disease|leukemia type|type leukemia|Leukemia, no International Classification of Diseases for Oncology subtype (morphologic abnormality)|Leukemia of unspecified cell type | leukemia |
C0876248 | null | immunologic preparation|immunological agent|agents immunologic|Immunotherapeutic agent (product)|Immunologic agent (substance)|Immunologic agent|Immunotherapeutic agent|immunotherapeutic agent | Immunotherapeutic agent |
C0876248 | null | immunologic preparation|immunological agent|agents immunologic|Immunotherapeutic agent (product)|Immunologic agent (substance)|Immunologic agent|Immunotherapeutic agent|immunotherapeutic agent | Immunotherapeutic agent |
C0918027 | null | ok432|OK 432|OK432|Streptococcal OK 432|Streptococcal Preparation OK 432|Streptococcal OK-432|Streptococcal Preparation OK432|Streptococcal OK432|Streptococcal Preparation OK-432|OK-432|ok-432|ok 432|432 ok | OK-432 |
C0123759 | A heterodimeric cytokine that plays a role in innate and adaptive immune responses. Interleukin-12 is a 70 kDa protein that is composed of covalently linked 40 kDa and 35 kDa subunits. It is produced by DENDRITIC CELLS; MACROPHAGES and a variety of other immune cells and plays a role in the stimulation of INTERFERON-GAMMA production by T-LYMPHOCYTES and NATURAL KILLER CELLS. | Interleukin 12 p70|IL-12|interleukin 12|Interleukin 12|IL-12 p70|IL-12p70|Interleukin-12 p70|Natural Killer Cell Stimulatory Factor|NKSF|Cytotoxic lymphocyte maturation factor|IL 12|il-12|IL12|Interleukin-12 (substance)|il 12|Cytotoxic Lymphocyte Maturation Factor|Interleukin-12|interleukin-12|CLMF | interleukin-12 |
C0383327 | A cytokine which resembles IL-1 structurally and IL-12 functionally. It enhances the cytotoxic activity of NK CELLS and CYTOTOXIC T-LYMPHOCYTES, and appears to play a role both as neuroimmunomodulator and in the induction of mucosal immunity. | Inducing Factor, IFN-gamma|IFN-gamma Inducing Factor|il18|interferon gamma inducing factor|18 interleukin|IFN gamma Inducing Factor|interleukin-18|Inducing Factor, Interferon-gamma|Interferon-gamma Inducing Factor|IFN-gamma-Inducing Factor|IL-18|Interferon-gamma-Inducing Factor|Interleukin 18|interleukin 18|IL18|il-18|Interleukin-18|Interferon gamma Inducing Factor|Interleukin 18 (substance) | Interleukin-18 |
C1321301 | A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes. | PBMC|Peripheral Blood Mononuclear Cell|Peripheral Blood Mononuclear cells|PERIPHERAL BLOOD MONONUCLEAR CELL|Peripheral blood monocyte|Peripheral blood mononuclear cell|Peripheral blood mononuclear cell (cell) | Peripheral blood mononuclear cell (cell) |
C0598934 | null | tumor growth|growth tumor|growths tumors|growths tumor | tumor growth |
C0918027 | null | ok432|OK 432|OK432|Streptococcal OK 432|Streptococcal Preparation OK 432|Streptococcal OK-432|Streptococcal Preparation OK432|Streptococcal OK432|Streptococcal Preparation OK-432|OK-432|ok-432|ok 432|432 ok | OK-432 |
C0027819 | A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) | Neuroblastoma|neuroblastomas|Neuroblastoma (disorder)|NB - Neuroblastoma|Neuroblastoma (Schwannian Stroma-Poor)|NEUROBLASTOMA, MALIGNANT|neuroblastoma|Neural Crest Tumor, Malignant|Neuroblastoma (morphologic abnormality)|Neuroblastomas|Neuroblastoma (Schwannian Stroma-poor)|NEUROBLASTOMA|Neuroblastoma, NOS|Cancer of early nerve cells | Neuroblastoma |
C0543488 | A state of curiosity or concern about or attention to something. | Interested (finding)|interesting|interest|interests|Interest|interested | Interested |
C0596087 | Agents and endogenous substances that antagonize or inhibit the development of new blood vessels. | Agents, Angiostatic|Angiogenic Antagonists|Substance with angiogenesis inhibitor mechanism of action (substance)|Angiogenesis Antagonists|Angiogenetic Antagonists|Angiogenetic Inhibitors|angiogenesis inhibitor|Antiangiogenic Agent|angiogenetic inhibitor|Neovascularization inhibitors|angiogenic inhibitors|Anti-Angiogenetic Agents|Antagonists, Angiogenic|Angiogenesis Inhibitors|Anti Angiogenetic Agents|anti angiogenic drug|Anti Angiogenic Drugs|Antiangiogenic Agents|Anti-Angiogenic Agents|Inhibitors, Neovascularization|Agents, Antiangiogenic|Angiostatic Agents|neovascularization inhibitors|Angiogenesis inhibitor-containing product|Neovascularization Inhibitors|Inhibitors, Angiogenetic|angiogenesis inhibitors|Inhibitors, Angiogenesis|Angiogenesis inhibitor|Angiogenesis Inhibitor|anti-angiogenic drugs|Anti-Angiogenic Drugs|Product containing angiogenesis inhibitor (product)|Agents, Anti-Angiogenetic|Angiogenic Inhibitors|Antiangiogenesis Agents|Substance with angiogenesis inhibitor mechanism of action|Angiogenesis Blockers|Drugs, Anti-Angiogenic|Antagonists, Angiogenetic|antiangiogenic|Inhibitors, Angiogenic|antiangiogenic agents | Angiogenesis Inhibitors |
C0014261 | Single pavement layer of cells which line the luminal surface of the entire vascular system and regulate the transport of macromolecules and blood components. | Endotheliums, Vascular|Vascular Endothelium|Vascular Endotheliums|vascular endothelium|Vascular endothelium | Endothelium, Vascular |
C0060527 | null | FITC-dextran|fluoresceinthiocarbamoyl dextrans|FITC dextrans | fluorescein isothiocyanate dextran |
C0023828 | Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. | liposomes|Liposomes|liposomal|Liposome|liposome | Liposomes |
C0023828 | Artificial, single or multilaminar vesicles (made from lecithins or other lipids) that are used for the delivery of a variety of biological molecules or molecular complexes to cells, for example, drug delivery and gene transfer. They are also used to study membranes and membrane proteins. | liposomes|Liposomes|liposomal|Liposome|liposome | Liposomes |
C0029923 | An albumin obtained from the white of eggs. It is a member of the serpin superfamily. | Ovalbumins|ovalbumin|Ovalbumin (substance)|OVALBUMIN|Ovalbumin|Serpin B14 | ovalbumin |
C0029923 | An albumin obtained from the white of eggs. It is a member of the serpin superfamily. | Ovalbumins|ovalbumin|Ovalbumin (substance)|OVALBUMIN|Ovalbumin|Serpin B14 | ovalbumin |
C0042196 | Administration of vaccines to stimulate the host's immune response. This includes any preparation intended for active immunological prophylaxis. | active immunization|VACCINATION|vaccinations|inoculation|Inoculation, NOS|vaccination|Inoculation|Inoculations - prophylactic|Vaccinations|Vaccination, NOS|immunization|Vaccination NOS|inoculations|immunisation|Vaccination | Vaccination |
C0243038 | A carcinoma discovered by Dr. Margaret R. Lewis of the Wistar Institute in 1951. This tumor originated spontaneously as a carcinoma of the lung of a C57BL mouse. The tumor does not appear to be grossly hemorrhagic and the majority of the tumor tissue is a semifirm homogeneous mass. (From Cancer Chemother Rep 2 1972 Nov;(3)1:325) It is also called 3LL and LLC and is used as a transplantable malignancy. | Lung Carcinoma, Lewis|Lewis Lung Carcinoma | Carcinoma, Lewis Lung |
C1336777 | RNA polymerase II transcription of Class II genes involves the TFIID transcription complex comprised of general factors, including TBP, TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIG/J, and TFIIH, as well as gene-specific factors that include TAFs, which interact with regulatory protein activation domains to enhance transcription. A second group of cofactors includes PC1, PC2, and PC3, which have a strong positive influence on transcription. The combined action of general and gene-specific regulators encoded by Transcription Coactivator Genes enhances gene expression. (NCI) | null | Transcription Coactivator Gene |
C1336777 | RNA polymerase II transcription of Class II genes involves the TFIID transcription complex comprised of general factors, including TBP, TFIIA, TFIIB, TFIID, TFIIE, TFIIF, TFIIG/J, and TFIIH, as well as gene-specific factors that include TAFs, which interact with regulatory protein activation domains to enhance transcription. A second group of cofactors includes PC1, PC2, and PC3, which have a strong positive influence on transcription. The combined action of general and gene-specific regulators encoded by Transcription Coactivator Genes enhances gene expression. (NCI) | null | Transcription Coactivator Gene |
C0021757 | A multilineage cell growth factor secreted by LYMPHOCYTES; EPITHELIAL CELLS; and ASTROCYTES which stimulates clonal proliferation and differentiation of various types of blood and tissue cells. | Muplestim|Hematopoietin-2|interleukin 3|Interleukin 3|Eosinophil Mast Cell Growth Factor|Hematopoietin 2|Colony Stimulating Factor, Multipotential|interleukin-3|Colony Stimulating Factor, Mast Cell|Eosinophil-Mast Cell Growth-Factor|Burst Promoting Factor, Erythrocyte|IL-3|IL3|Interleukin-3|P Cell Stimulating Factor|Interleukin-3 (substance)|Erythrocyte Burst Promoting Factor|P-Cell Stimulating Factor|Colony-stimulating factor, multiple|Colony-Stimulating Factor, Multipotential|Colony-Stimulating Factor 2 Alpha|Burst-Promoting Factor, Erythrocyte|il-3|INTERLEUKIN-3|Multi-CSF|Multipotential colony-stimulating factor|Mast-Cell Colony-Stimulating Factor|Colony-Stimulating Factor, Mast-Cell|Multipotential Colony-Stimulating Factor|Erythrocyte Burst-Promoting Factor|Multipotential Colony Stimulating Factor | interleukin-3 |
C0021757 | A multilineage cell growth factor secreted by LYMPHOCYTES; EPITHELIAL CELLS; and ASTROCYTES which stimulates clonal proliferation and differentiation of various types of blood and tissue cells. | Muplestim|Hematopoietin-2|interleukin 3|Interleukin 3|Eosinophil Mast Cell Growth Factor|Hematopoietin 2|Colony Stimulating Factor, Multipotential|interleukin-3|Colony Stimulating Factor, Mast Cell|Eosinophil-Mast Cell Growth-Factor|Burst Promoting Factor, Erythrocyte|IL-3|IL3|Interleukin-3|P Cell Stimulating Factor|Interleukin-3 (substance)|Erythrocyte Burst Promoting Factor|P-Cell Stimulating Factor|Colony-stimulating factor, multiple|Colony-Stimulating Factor, Multipotential|Colony-Stimulating Factor 2 Alpha|Burst-Promoting Factor, Erythrocyte|il-3|INTERLEUKIN-3|Multi-CSF|Multipotential colony-stimulating factor|Mast-Cell Colony-Stimulating Factor|Colony-Stimulating Factor, Mast-Cell|Multipotential Colony-Stimulating Factor|Erythrocyte Burst-Promoting Factor|Multipotential Colony Stimulating Factor | interleukin-3 |
C0007457 | A group distinguished by classification according to physical features. This group, also called Europoid, centers around the Mediterranean Sea but includes other parts of Europe. (from Winick: Dictionary of Anthropology, 1972; American Heritage Dictionary, 2d College ed) | Caucasian Race|caucasian|Caucasian|White|Caucasoid Race|CAUCASIAN RACE|Occidental|Race, Caucasian|Caucasian Races|Caucasoid|WHITE|Races, Caucasian|Race: White|Races, Caucasoid|Caucasoid Races|Caucasian (racial group)|Caucasian race|white|Race, Caucasoid|Whites|white race|Caucasoid race|Caucasians | Caucasoid Race |
C0079460 | An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages. | Tumor-Cell Human GM Colony-Stimulating Factor|Colony Stimulating Factor 2|Granulocyte-Macrophage Colony Stimulating Factor|GM CSF|CSF|granulocyte-macrophage colony-stimulating factor|GM-CSF|Granulocyte macrophage colony stimulating factor|Colony-Stimulating Factor, Granulocyte-Macrophage|gm-cfs|CSF2|Colony-stimulating factor, granulocyte-macrophage|CSF-2|Colony Stimulating Factor, Granulocyte-Macrophage|Granulocyte Macrophage Colony-Stimulating Factor|Cell-Stimulating Factor, Histamine-Producing|gm-csf|CSF-GM|Colony-stimulating factor 2|gmcsf|TC-GM-CSF|granulocyte macrophage colony-stimulating factor|Colony Stimulating Factor, Granulocyte Macrophage|Granulocyte-macrophage colony-stimulating factor|Colony-stimulating factor, granulocyte-macrophage (substance)|Colony-Stimulating Factor|Histamine Producing Cell Stimulating Factor|granulocyte-macrophage colony stimulating factor|gm csf|Histamine-Producing Cell-Stimulating Factor|histamine producing cell stimulating factor|Granulocyte Macrophage Colony Stimulating Factor|Colony-Stimulating Factor 2|granulocyte macrophage colony stimulating factor|Tumor Cell Human GM Colony Stimulating Factor|GMCSF (granulocyte macrophage colony stimulating factor)|GMCSF|Granulocyte-Macrophage Colony-Stimulating Factor | Granulocyte-Macrophage Colony-Stimulating Factor |
C0242732 | The directional growth of an organism in response to an external stimulus such as light, touch, or gravity. Growth towards the stimulus is a positive tropism; growth away from the stimulus is a negative tropism. (From Concise Dictionary of Biology, 1990) | tropism|Tropisms|tropisms | Tropism |
C0039198 | CD4-positive T cells that inhibit immunopathology or autoimmune disease in vivo. They inhibit the immune response by influencing the activity of other cell types. Regulatory T-cells include naturally occurring CD4+CD25+ cells, IL-10 secreting Tr1 cells, and Th3 cells. | Regulatory T Cells|T Lymphocytes, Regulatory|T-Cells, Regulatory|Treg Cell|Regulatory T-Lymphocytes|T Cells, Regulatory|Regulatory T Lymphocytes|Cells, Treg|T-Lymphocyte, Regulatory|Regulatory T cell|Treg Cells|T-Lymphocytes, Regulatory|Regulatory T-Cells|Cell, Treg|Regulatory T-Lymphocyte | Regulatory T-Lymphocytes |
C1327414 | The regulated release of cytokines from a cell. Cytokines are any of a group of proteins that function to control the survival, growth and differentiation of tissues and cells, and which have autocrine and paracrine activity. [GOC:ai, GOC:bf, ISBN:0198599471] | null | cytokine secretion |
C0314768 | toxic substances produced by certain bacteria, that are found outside the bacterial cell or free in the culture medium; they are heat labile proteins and are among the most poisonous substances known; some fungi also produce exotoxins. | Exotoxin|Exotoxin, bacterial|Bacterial exotoxin|exotoxin|Bacterial exotoxin, NOS|Bacterial exotoxin (substance) | Bacterial exotoxin |
C0655013 | A fusion protein consisting of the Fv portion of a monoclonal antibody attached to a 38-kDa fragment of the Pseudomonas exotoxin A (with amino acids 365-380 deleted). LMB-2 immunotoxin targets the interleukin 2 receptor (also known as IL-2R or CD25) which is expressed on activated normal T and B cells and macrophages and on the cells of various hematologic malignancies. The antibody attaches to the IL-2R on the cell membrane, facilitating the entry of the exotoxin. The exotoxin moiety induces caspase-mediated apoptosis of tumor cells via a mechanism involving mitochondrial damage; it also catalyzes the transfer of ADP ribose from nicotinamide adenine dinucleotide (NAD) to elongation factor-2 in eukaryotic cells, thereby inactivating elongation factor 2 and inhibiting protein synthesis. (NCI04) | Humanized AntiTac Toxin|LMB-2 (Anti-TAC(FV)-PE-38)|LMB-2|Immunotoxin LMB-2|LMB-2 Immunotoxin|immunotoxin LMB-2|humanized antiTac toxin|LMB-2 (anti-TAC(FV)-PE-38)|Anti-Tac(Fv)-PE38|LMB-2 immunotoxin|anti-Tac(Fv)-PE38|B3(Fv)-PE38KDEL | B3(Fv)-PE38KDEL recombinant immunotoxin |
C0050943 | null | AG-3-5 compound | AG 3-5 |
C0278488 | null | breast cancer iv stage|breast cancer, stage IV|breast cancer stage iv|breast cancer, metastatic|stage IV breast cancer|metastatic breast cancer|breast cancer metastatic | Carcinoma breast stage IV |
C0021489 | The forcing into the skin of liquid medication, nutrient, or other fluid through a hollow needle, piercing the top skin layer. | intradermal injection|intradermal injections|Intradermal Injections|Injections, Intradermal|Intradermal injection (procedure)|Injection, Intradermal|Intradermal Injection|Intradermal injection | intradermal injection |
C0014020 | Colloids formed by the combination of two immiscible liquids such as oil and water. Lipid-in-water emulsions are usually liquid, like milk or lotion. Water-in-lipid emulsions tend to be creams. The formation of emulsions may be aided by amphiphatic molecules that surround one component of the system to form MICELLES. | Emulsion|Emulsions|emulsion|emulsions | Emulsions |
C0004096 | A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). | ASTHMA BRONCHIAL|Asthmas|br asthma|Airway hyperreactivity|ASTHMA, BRONCHIAL|Asthma (disorder)|Asthma, unspecified|Bronchial asthma|bronchitic asthma|Asthma, NOS|Bronchial asthma, NOS|asthma|bronchial asthma|Asthma|asthmatics|Asthma, Bronchial|Asthmatic|asthma disorders|BRONCHIAL ASTHMA|ASTHMA|asthmatic|Bronchial Asthma | Asthma |
C0022108 | Drugs that act locally on cutaneous or mucosal surfaces to produce inflammation; those that cause redness due to hyperemia are rubefacients; those that raise blisters are vesicants and those that penetrate sebaceous glands and cause abscesses are pustulants; tear gases and mustard gases are also irritants. | Irritant (product)|chemical irritants|Irritants|Irritant (substance)|irritants|Irritant-containing product|Product containing irritant (product)|irritant|Irritant | Irritants |
C0038777 | A highly toxic, colorless, nonflammable gas. It is used as a pharmaceutical aid and antioxidant. It is also an environmental air pollutant. | SO2|sulfur dioxide|Sulfurous anhydride|Sulfurous Anhydride|Sulphurous anhydride|Sulfur Dioxide|so2|Sulphur dioxide|sulphur dioxide|SULFUR DIOXIDE|Sulfur dioxide|Sulfur dioxide (substance) | sulfur dioxide |
C0016327 | Inorganic salts of hydrofluoric acid, HF, in which the fluorine atom is in the -1 oxidation state. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Sodium and stannous salts are commonly used in dentifrices. | Fluoride Ion|Fluoride (substance)|Fluorides|Fluoride, NOS|Fluoride|fl|F-|FLUORIDE|FLUORIDE ION|Fluoride-containing product|Product containing fluoride (medicinal product)|fluoride|Fluoride salt, NOS|Fluorine-|fluorides|fluoride (FL)|fluoride products|Fluoride salt | Fluorides |
C0032529 | The regular and simultaneous occurrence in a single interbreeding population of two or more discontinuous genotypes. The concept includes differences in genotypes ranging in size from a single nucleotide site (POLYMORPHISM, SINGLE NUCLEOTIDE) to large nucleotide sequences visible at a chromosomal level. | Polymorphisms (Genetics)|Genetic polymorphism|Genetic Polymorphism|Polymorphism (Genetics)|Genetic polymorphism (finding)|Genetic Polymorphisms|polymorphism|Polymorphism, Genetic|genetic polymorphism|Polymorphisms, Genetic|Polymorphism|polymorphisms|Genetic polymorphisms | Genetic Polymorphism |
C0238690 | null | ARSENIC EXPOSURE|arsenic exposure | contact exposure to arsenic (history) |
C1550262 | null | null | Gluteal |
C0043251 | Damage inflicted on the body as the direct or indirect result of an external force, with or without disruption of structural continuity. | Wounds and Injuries|Wounds, Injury|Injuries and Wounds|Wounds and injuries|injury traumatic|Injuries, Wounds|Injury and Wounds|Wounds and Injury|injuries wounds|Trauma|injuries wound|Traumas|Traumatic injuries|wounds injuries | Wounds and Injuries |
C0560563 | null | Fluoroscopic guidance (procedure) | Fluoroscopic guidance |
C0013119 | null | Medical dressing (physical object)|Dressing, NOS|DRESSING|Medical dressing|dressings|dressing|sterile wound covering|Dressings|Dressing | Medical dressing |
C0015455 | The facial skeleton, consisting of bones situated between the cranial base and the mandibular region. While some consider the facial bones to comprise the hyoid (HYOID BONE), palatine (HARD PALATE), and zygomatic (ZYGOMA) bones, MANDIBLE, and MAXILLA, others include also the lacrimal and nasal bones, inferior nasal concha, and vomer but exclude the hyoid bone. (Jablonski, Dictionary of Dentistry, 1992, p113) | FACIAL BONE|Bone structure of face|Bone of face|ossa faciei|Facial Bone|Bone of face structure|Bone of Face|Facial bones|bone face|facial bones|Facial bone|facial bone|Facial bone structure|Facial Bones|Bone, Facial|Bones, Facial|Bone structure of face (body structure)|Set of facial bones|bones facial|bones face|Facial bones, NOS|facial bone structure | Bone structure of face |
C0036098 | Glands that secrete SALIVA in the MOUTH. There are three pairs of salivary glands (PAROTID GLAND; SUBLINGUAL GLAND; SUBMANDIBULAR GLAND). | Salivary Gland Types and Structures|Salivary Gland|Salivary Glands|Head and Neck, Salivary Glands|GLAND, SALIVARY|Salivary gland, NOS|Salivary structure|Salivary structure (body structure)|salivary gland|Gland, Salivary|Glandula salivaria|Salivary glands|SALIVARY GLANDS: TYPE AND STRUCTURE|SALIVARY GLANDS|SALIVARY GLAND|Glands, Salivary|Salivary gland|salivary glands|Salivary gland structure|Salivary gland structure (body structure)|Salivary apparatus | Salivary Glands |
C1285092 | An organ that produces and secretes hormones (e.g. endocrine gland), saliva or sweat (e.g. exocrine gland). | Gland|Gland structure|Glands set|Gland structure (body structure)|Glandular|Set of glands|gland|Glandula|glands|Glands|Gland, NOS|Organ component gland | Gland |
C0860877 | null | null | Salivary scintigraphy |
C0348024 | null | thyroid dysfunction|Thyroid dysfunction (disorder)|dysfunction thyroid|DYSFUNCTION THYROID|THRYOID DYSFUNCTION | Thyroid dysfunction |
C1101698 | null | restylane | Restylane |
C0225317 | Refers to muscle, fat, fibrous tissue, blood vessels, or other supporting tissue of the body. | Soft Tissues|Soft tissues, NOS|soft tissue|Soft tissue|Soft tissues (body structure)|Soft tissue (navigational concept)|Soft Tissue|soft tissues|SOFT TISSUES|Soft tissues|SOFT TISSUE | soft tissue |
C1331418 | A feeling of freedom from constraint or embarrassment; feeling relaxed and natural. | Comfort|Ease | Comfort |
C0339897 | A type of surgical portasystemic shunt to reduce portal hypertension with associated complications of esophageal varices and ascites. It is performed percutaneously through the jugular vein and involves the creation of an intrahepatic shunt between the hepatic vein and portal vein. The channel is maintained by a metallic stent. The procedure can be performed in patients who have failed sclerotherapy and is an additional option to the surgical techniques of portocaval, mesocaval, and splenorenal shunts. It takes one to three hours to perform. (JAMA 1995;273(23):1824-30) | Shunt, Transjugular Intrahepatic Portasystemic|TIPS|Transjugular Intrahepatic Portasystemic Shunt|Shunt, Transjugular Intrahepatic Portosystemic|Transjugular Intrahepatic Portosystemic Shunt|Transjugular intrahepatic portosystemic shunt|TIPSS|TIPS - Transjugular intrahepatic portosystemic shunt|Portasystemic Shunt, Transjugular Intrahepatic|Transjugular intrahepatic portosystemic shunt (procedure)|Portosystemic Shunt, Transjugular Intrahepatic | Transjugular intrahepatic portosystemic shunt procedure |
C0175649 | A device which is an artificial substitute for a missing body part or function; used for functional or cosmetic reasons, or both. | prosthesis|Prosthesis, device (physical object)|Prosthesis|prosthetic device|devices prosthetic|prostheses|PROSTHESES|Prostheses|Prosthesis, NOS|Prosthesis, device|prosthetic devices|device prosthetic | Prosthesis |
C0333276 | null | Acute blood loss|acute blood loss|Acute bleeding|Acute haemorrhage|Acute hemorrhage (morphologic abnormality)|Acute hemorrhage|acute bleed|acute hemorrhage|acute bleeding | Acute hemorrhage |
C0023690 | Application of a ligature to tie a vessel or strangulate a part. | Ligation|Ligation, NOS|Ligation - action|surgical binding|Ligation (procedure)|ligation|Ligation - action (qualifier value)|Closure by ligation|Closure by Ligation|Ligations|Closure by ligation, NOS | Ligation |
C0034115 | A procedure in which fluid is withdrawn from a body cavity or organ via a trocar and cannula, needle, or other hollow instrument. | Paracenteses|Puncture and drainage|Centesis|Paracentesis|Centesis (procedure)|Centesis, NOS|Puncture and aspiration|Puncture and Aspiration|Needling and drainage|Aspiration and Puncture|abdominal tapping|Puncture and Drainage|Tap|Drainage and Puncture|Centeses|paracentesis | Paracentesis |
C0086565 | A finding that indicates abnormal liver function. | liver dysfunction|Hepatic dysfunction|Liver dysfunction|Abnormal hepatic function|Liver function, abnormal|Abnormal liver function|Dysfunctions, Liver|hepatic function disorder|impaired liver function|FUNCTION LIVER ABNORMAL|abnormal functions liver|Liver Dysfunction|Abnormal liver function (finding)|abnormal liver function|Impaired liver function|HEPATIC FUNCTION ABNORMAL|hepatic dysfunction|Liver Dysfunctions|Dysfunction, Liver | Liver Dysfunction |
C0151317 | Presence of a protracted or persistent infection by a pathogen potentially related to an underlying abnormality of the immune system that is not able to clear the infection. [] | chronic infection|Chronic infectious disease (disorder)|chronic infections|Infection, chronic|Chronic infectious disease|infection chronic|chronic disease infectious|Chronic infection | Chronic infectious disease |
C0019163 | INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. | Hepatitis B|viral hepatitis b|Hepatitis B Infection|Hepatitis B Virus Infection|hepatitis viral b|serum hepatitis|SH - Serum hepatitis|Viral Hepatitis B|Viral hepatitis, type B|Hepatitis B infection|hepatitis b viral|Serum hepatitis|Type B viral hepatitis|hepatitis B infection|hepatitis B|HBV|Viral hepatitis type B|b viral hepatitis|Viral hepatitis type B (disorder)|HEPATITIS, SERUM|HEPATITIS B|hepatitis b | Hepatitis B |
C0019682 | Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. | Lymphadenopathy-Associated Virus|Human T Cell Leukemia Virus Type III|Human T Lymphotropic Virus Type III|Virus-HIV|AIDS Viruses|Virus, AIDS|human immunodeficiency virus|Human T-Cell Lymphotropic Virus Type III|AIDS Virus|Virus, Human Immunodeficiency|Human Immunodeficiency Virus (HIV)|HIV, Human Immunodeficiency Virus|Immunodeficiency Virus, Human|Acquired Immune Deficiency Syndrome Virus|Human immunodeficiency virus (organism)|lymphadenopathy associated virus|HTLV-III|AIDS virus|human immunodeficiency virus (HIV)|Acquired Immunodeficiency Syndrome Virus|Immunodeficiency Viruses, Human|Viruses, AIDS|LAV|htlv iii|HIV|htlv-iii|Human Immunodeficiency Virus|Viruses, Human Immunodeficiency|Viruses, Lymphadenopathy-Associated|Human T Cell Lymphotropic Virus Type III|Virus, Lymphadenopathy-Associated|Human immunodeficiency virus|Human immunodeficiency virus, NOS|Lymphadenopathy Associated Virus|HIV - Human immunodeficiency virus|Human T-Cell Leukemia Virus Type III|LAV-HTLV-III|Human T-Lymphotropic Virus Type III|Virus (HIV), Human Immunodeficiency|HTLV III|Human Immunodeficiency Viruses|Lymphadenopathy-Associated Viruses | HIV |
C0238607 | null | AIDS PATIENT|AIDS patient|AIDS patients | AIDS patient |
C0019209 | Enlargement of the liver. | Large liver|Enlargement of liver|enlarged liver|enlarged livers|HEPATOMEGALY|liver enlargement|hepatomegaly|Enlarged Liver|LIVER ENLARGEMENT|hepatic enlargement|Enlarged liver|LARGE LIVER|Liver, Enlarged|Large liver (disorder)|Hepatomegaly|enlargement of liver|large liver|Liver enlarged | Hepatomegaly |
C0271899 | null | normochromic normocytic anemia|Normocytic normochromic anemia|Normocytic normochromic anaemia|anemia normochromic normocytic|normochromic normocytic anaemia|normocytic normochromic anemia|Normocytic normochromic anemia (disorder) | Normocytic normochromic anemia |
C0302314 | A non-neoplastic disorder characterized by a localized collection of histiocytes containing lipid. Xanthomas usually occur in the skin and subcutaneous tissues, but occasionally they may involve the deep soft tissues. -- 2003 | Xanthelasmas|Xanthomata|xanthelasma|xanthomas|Xanthoma|Xanthomatous deposition|xanthelasmas|xanthoma|Deposition, xanthomatous|Xanthomatous Depositions|Xanthomas|Xanthoma, NOS|Xanthomatous deposition, NOS|Xanthomatous deposition (morphologic abnormality)|XANTHOMA|Xanthelasma | Xanthoma |
C1278075 | null | Serum alanine level|Serum alanine measurement (procedure) | Serum alanine measurement |
C0019151 | A syndrome characterized by central nervous system dysfunction in association with LIVER FAILURE, including portal-systemic shunts. Clinical features include lethargy and CONFUSION (frequently progressing to COMA); ASTERIXIS; NYSTAGMUS, PATHOLOGIC; brisk oculovestibular reflexes; decorticate and decerebrate posturing; MUSCLE SPASTICITY; and bilateral extensor plantar reflexes (see REFLEX, BABINSKI). ELECTROENCEPHALOGRAPHY may demonstrate triphasic waves. (From Adams et al., Principles of Neurology, 6th ed, pp1117-20; Plum & Posner, Diagnosis of Stupor and Coma, 3rd ed, p222-5) | Encephalopathy, Portal-Systemic|Encephalopathy, Portal Systemic|hepatocerebral syndrome|hepatic coma/encephalopathy|Encephalopathies, Portosystemic|ENCEPHALOPATHY, PORTAL-SYSTEMIC|Encephalopathies, Portal-Systemic|encephalopathy portosystemic|portal systemic encephalopathy|Hepatocerebral Encephalopathies|ENCEPHALOPATHY HEPATIC|Portal-systemic encephalopathy|Portal Systemic Encephalopathy|Hepatic encephalopathy|coma hepaticum|Portal systemic encephalopathy|portosystemic encephalopathy|Encephalopathies, Hepatic|Hepatic encephalopathy syndrome|Encephalopathies, Hepatocerebral|Portosystemic Encephalopathies|Transient hepatargy syndrome|Encephalopathy, Portosystemic|Portal systemic encephalopathy (disorder)|Hepatic Encephalopathies|Hepatocerebral encephalopathy|Encephalopathy, Hepatocerebral|Portosystemic Encephalopathy|portacaval encephalopathy|Hepatic encephalopathy (disorder)|Hepatic Encephalopathy|Encephalopathy, Hepatic|Portal-Systemic Encephalopathy|hepatic encephalopathy|ENCEPHALOPATHY, HEPATIC|HE - Hepatic encephalopathy|portal-systemic encephalopathy|Portosystemic encephalopathy|HEPATIC ENCEPHALOPATHY|Gaustad's syndrome|Hepatocerebral Encephalopathy|Portal-Systemic Encephalopathies|encephalopathy hepatic | Hepatic Encephalopathy |
C0020615 | A syndrome of abnormally low BLOOD GLUCOSE level. Clinical hypoglycemia has diverse etiologies. Severe hypoglycemia eventually lead to glucose deprivation of the CENTRAL NERVOUS SYSTEM resulting in HUNGER; SWEATING; PARESTHESIA; impaired mental function; SEIZURES; COMA; and even DEATH. | Hypoglycemic syndrome, NOS|Hypoglycaemia, NOS|Hypoglycemia|Hypoglycemia, unspecified|HYPOGLYCAEMIA|low blood sugar level|Low Blood Sugar|Hypoglycemic disorder|Hypoglycaemic disorder|hypoglycemia nos|Hypoglycaemic syndrome, NOS|Glucose, Low Blood|Blood Glucose, Low|Low blood sugar|Hypoglycaemia|Hypoglycemic disorder (disorder)|Hypoglycemia (disorder)|Hypoglycemic syndrome|hypoglycaemia|Low Blood Glucose|Hypoglycemia NOS|Hypoglycemia, NOS|HYPOGLYCEMIA|Hypoglycaemic syndrome|hypoglycemia|Hypoglycemic syndrome (disorder) | Hypoglycemia |
C0085584 | A functional and/or structural disorder of the brain caused by diseases (e.g. liver disease, kidney disease), medications, chemicals, and injuries. | encephalopathy|ENCEPHALOPATHY|encephalopathy unspecified|Encephalopathy, not elsewhere classified|Encephalopathy, NOS|encephalopathies|encephalopathy nos|Encephalopathy, unspecified|Encephalopathy|Encephalopathies|brain syndromes|brain syndrome|unspecified brain disease | Encephalopathies |
C0020649 | Abnormally low BLOOD PRESSURE that can result in inadequate blood flow to the brain and other vital organs. Common symptom is DIZZINESS but greater negative impacts on the body occur when there is prolonged depravation of oxygen and nutrients. | bp lower|low bp|Low blood pressure|Vascular Hypotension|HYPOTENSION|low blood pressures|Low Blood Pressure|Hypotension|blood falls pressure|Hypotension, unspecified|Arterial hypotension|blood drops pressure|Low blood pressure (disorder)|Hypopiesis|blood lowered pressure|PRESSURE ARTERIAL DECREASED|Arterial hypotension, NOS|blood lowers pressure|blood pressure lower|Systemic hypotension|BLOOD PRESSURE LOW|Arterial hypotension NOS|blood drop pressure|Hypotension, NOS|lower blood pressure|ARTERIAL BLOOD PRESSURE DECREASED|low blood pressure|BLOOD PRESSURE DECREASED|blood lowing pressure|blood pressure drop|hypotension|hypotension arterial|decreased blood pressure|HYPOTENSIVE DISEASES|hypopiesis|Hypotension NOS|blood decreasing pressure|arterial hypotension|Hypotension, Vascular|blood falling pressure|dropped blood pressure|blood dropping pressure|BLOOD PRESSURE DROP ARTERIAL|blood pressure low|Vascular Hypotensive Disorder|drop in blood pressure|Blood Pressure, Decreased|Decreased Blood Pressure|LBP|Pressure, Low Blood|Blood Pressure, Low | Hypotension |
C0037221 | A congenital abnormality in which organs in the THORAX and the ABDOMEN are opposite to their normal positions (situs solitus) due to lateral transposition. Normally the STOMACH and SPLEEN are on the left, LIVER on the right, the three-lobed right lung is on the right, and the two-lobed left lung on the left. Situs inversus has a familial pattern and has been associated with a number of genes related to microtubule-associated proteins. | Situs Ambiguus|Visceral inversion|Complete transposition|situs inversus|Situs Inversus|SIV|situs transversus|inversus situs|Situs inversus|Situs Inversus Viscerum|Transposition, complete|Situs inversus viscerum (disorder)|SITUS INVERSUS VISCERUM|Inversus, Situs|Abdominal situs inversus|Situs inversus visceralis|Situs transversus|SITUS INVERSUS|situs viscerum inversus|Complete transposition (morphologic abnormality)|Situs inversus viscerum | Situs Inversus |
C0015980 | One of the type I interferons produced by fibroblasts in response to stimulation by live or inactivated virus or by double-stranded RNA. It is a cytokine with antiviral, antiproliferative, and immunomodulating activity. | beta-interferon|Beta interferon|Interferon, Fibroblast|beta Interferon|Interferon-beta|interferon beta|Beta Interferon|fibroblast interferon|Interferon beta-containing product|Product containing interferon beta (medicinal product)|Natural human interferon beta|beta interferons|IFNb|beta-Interferon|INTERFERON-BETA|Beta-Interferon|beta interferon|interferon beta natural|Fibroblast Interferon|Interferon beta (substance)|Endogenous Interferon Beta|interferon-beta|Interferon beta|Interferon, Beta|IFN-Beta|Interferon Beta, Natural|Interferon Beta|Interferon, beta | interferon-beta |
C0026769 | An autoimmune disorder mainly affecting young adults and characterized by destruction of myelin in the central nervous system. Pathologic findings include multiple sharply demarcated areas of demyelination throughout the white matter of the central nervous system. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia, and bladder dysfunction. The usual pattern is one of recurrent attacks followed by partial recovery (see MULTIPLE SCLEROSIS, RELAPSING-REMITTING), but acute fulminating and chronic progressive forms (see MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE) also occur. (Adams et al., Principles of Neurology, 6th ed, p903) | disseminated sclerosis|MS - Multiple sclerosis|Multiple sclerosis, NOS|SCLEROSIS, INSULAR|SCLEROSIS, DISSEMINATED|ms|multiple sclerosis|multiple sclerosis (MS)|Sclerosis, Multiple|Disseminated Sclerosis|Multiple sclerosis|multiple sclerosis MS|MS multiple sclerosis|multiples sclerosis|Disseminated sclerosis|Multiple sclerosis (disorder)|MS|MULTIPLE SCLEROSIS|SCLEROSIS MULTIPLE|Sclerosis, Disseminated|insular sclerosis|Generalized multiple sclerosis|MS (Multiple Sclerosis)|SCLEROSIS, MULTIPLE|DS - Disseminated sclerosis|Multiple Sclerosis | Multiple Sclerosis |
C0013456 | Pain in the ear. | otalgia|ear pain|EAR PAIN|pain in the ear|Pain in ear|Otalgia (finding)|Otalgias|Pain in ear, NOS|Earache, NOS|Earache NOS|Ear ache|Earaches|Otalgia|Earache symptom|earaches|Otalgia, unspecified|Earache symptom (finding)|Ear Pain|OTALGIA|ear pains|Pain in the ear|ear aches|Otalgia, NOS|pain in ear|PAIN EAR|ears pain|Earache|Earache symptoms|earache|Ear pain|EARACHE | Earache |
C0013456 | Pain in the ear. | otalgia|ear pain|EAR PAIN|pain in the ear|Pain in ear|Otalgia (finding)|Otalgias|Pain in ear, NOS|Earache, NOS|Earache NOS|Ear ache|Earaches|Otalgia|Earache symptom|earaches|Otalgia, unspecified|Earache symptom (finding)|Ear Pain|OTALGIA|ear pains|Pain in the ear|ear aches|Otalgia, NOS|pain in ear|PAIN EAR|ears pain|Earache|Earache symptoms|earache|Ear pain|EARACHE | Earache |
C0019158 | INFLAMMATION of the LIVER. | Inflammatory disorder of liver|HEPATITIS NONSPECIFIC|Hepatitis, unspecified|Hepatitis, NOS|Inflammatory liver disease|HEPATITIS|Liver inflammation|nonspecific hepatitis|inflammatory liver disease|hepatitides|Hepatitis|unspecified hepatitis|hepatitis|Inflammatory disease of liver|Hepatitides|Inflammatory disease of liver (disorder) | Hepatitis |
C0017710 | A group of CORTICOSTEROIDS that affect carbohydrate metabolism (GLUCONEOGENESIS, liver glycogen deposition, elevation of BLOOD SUGAR), inhibit ADRENOCORTICOTROPIC HORMONE secretion, and possess pronounced anti-inflammatory activity. They also play a role in fat and protein metabolism, maintenance of arterial blood pressure, alteration of the connective tissue response to injury, reduction in the number of circulating lymphocytes, and functioning of the central nervous system. | GLUCOCORTICOIDS|Glucocorticoid|Product containing glucocorticoid (product)|Glucocorticoid hormone (substance)|Therapeutic Glucocorticoid|glucocorticoids|Glucocorticoid hormone|glucocorticoid hormone|Glucocorticoids|Glucocorticoid-containing product|glucocorticoid hormones|glucocorticoid|glucocorticoids hormone|Glucocorticoid (substance) | Glucocorticoids |
C0033687 | The presence of proteins in the urine, an indicator of KIDNEY DISEASES. | Protein, urine, abnormal presence|Proteinurias|proteinuria|Proteinuria|Proteinuria, NOS|Protein in urine|Proteinuria (finding)|High urine protein levels|Abnormal presence of protein in urine|proteinurias|PROTEINURIA | Proteinuria |
C0011777 | An anti-inflammatory 9-fluoro-glucocorticoid. | dexamethasone (DMX)|Dexamethasone preparation|Fluoro-9alpha Methyl-16alpha Prednisolone|Dexamethasone (substance)|9alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione|16α-Methyl-9α-fluoro-1-dehydrocortisol|9Alpha-fluoro-11beta,17alpha,21-trihydroxy-16alpha-methylpregna-1,4-diene-3,20-dione|9Alpha-fluoro-16alpha-methylprednisolone|Dexaméthasone|Pregna-1,4-diene-3,20-dione, 9-fluoro-11,17,21-trihydroxy-16-methyl-, (11beta,16alpha)-|9alpha-Fluoro-16alpha- methylprednisolone|Dexametasona|DM|16alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione|Dexamethasonum|9alpha-Fluoro-16alpha-methylprednisolone|16Alpha-methyl-9alpha-fluoro-1,4-pregnadiene-11beta,17alpha,21-triol-3,20-dione|Dexamethasone|(11Beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione|Hexadecadrol|9α-Fluoro-16α-methylprednisolone|1-dehydro-16alpha-methyl-9alpha-fluorohydrocortisone|DEXAMETHASONE|Dexamethasone-containing product|Product containing dexamethasone (medicinal product)|DXM|16Alpha-methyl-9alpha-fluoroprednisolone|dexamethasone|16Alpha-methyl-9alpha-fluoro-delta1-hydrocortisone|16alpha-Methyl-9alpha-fluoro-1-dehydrocortisol|16alpha-methyl-9alpha-fluoroprednisolone|disaimisong|(11beta,16alpha)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione|Desamethasone|16alpha-methyl-9alpha-fluoro-delta1-hydrocortisone|Methylfluorprednisolone|1-Dehydro-16alpha-methyl-9alpha-fluorohydrocortisone|1-Dehydro-16α-methyl-9α-fluorohydrocortisone | dexamethasone |
C1563761 | Genes that are located on the MITOCHONDRIAL DNA. Mitochondrial inheritance is often referred to as maternal inheritance but should be differentiated from maternal inheritance that is transmitted chromosomally. | Mitochondrial Genes|Genes, Mitochondrial|Mitochondrial Gene|Gene, Mitochondrial | Genes, Mitochondrial |
C0042384 | Inflammation of any one of the blood vessels, including the ARTERIES; VEINS; and rest of the vasculature system in the body. | Vasculitides|Angiitides|vascular inflammation or infection|ANGIITIS|infection of the blood or lymph vessel|infection of the blood vessel|Vasculitis|VASCULITIS|Vasculitis, nonspecific|Angiitis, NOS|Inflammation of blood vessel|Vasculitis, NOS|Vasculitis (disorder)|angiitis|vasculitis|Angiitis | Vasculitis |
C0242599 | The process in which the neutrophil is stimulated by diverse substances, resulting in degranulation and/or generation of reactive oxygen products, and culminating in the destruction of invading pathogens. The stimulatory substances, including opsonized particles, immune complexes, and chemotactic factors, bind to specific cell-surface receptors on the neutrophil. | Activation, Neutrophil|Neutrophil Activation|neutrophil activation|Neutrophil Activations|Activations, Neutrophil | Neutrophil Activation |
C0011946 | A procedure to remove toxic substances from the blood that is used in patients with end-stage chronic kidney disease or acute kidney failure. This includes hemodialysis and peritoneal dialysis. | Dialysis Procedure|dialysis|Dialysis procedure (procedure)|Dialysis Therapy|Renal dialysis, NOS|dialysis therapy|Dialysis procedure|DIALYSIS PROCEDURES|Dialysis|dialysis procedure|therapy dialysis | Dialysis procedure |
C0007578 | Surface ligands, usually glycoproteins, that mediate cell-to-cell adhesion. Their functions include the assembly and interconnection of various vertebrate systems, as well as maintenance of tissue integration, wound healing, morphogenic movements, cellular migrations, and metastasis. | CAMs|cell adhesion molecule|Cell Adhesion Molecule|cell adhesion molecules|Cell adhesion molecule|Molecules, Cell Adhesion|cam|cams|Adhesion Molecule|CAM|Adhesion Molecules, Cell|Cell Adhesion Molecules|Cell adhesion molecules|cell adhesion molecules (CAM)|cell adhesion protein | Cell Adhesion Molecules |
C0003483 | The main trunk of the systemic arteries. | AORTA|Aortic structure|Aorta|Trunk of systemic arterial tree|Aortic|Aortic (qualifier value)|aortic|Aorta, NOS|ARTERY, AORTA|Aortic structure (body structure)|aorta|Trunk of aortic tree|Aortas | Aorta |
C0175895 | Having calcium deposited on or in an anatomic structure. | calcific|Calcified|calcium deposit|calcification|calcifications|calcium deposits|calcify|calcium deposition|calcifying|calcified | Calcified (qualifier) |
C0006674 | The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. | (1α,3β,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol|1,25-DHCC - 1,25-dihydroxycholecalciferol|1 alpha,25 Dihydroxyvitamin D3|D3, 1,25-Dihydroxyvitamin|9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1alpha,3beta,5Z,7E)-|1-alpha, 25-Dihydroxy cholecalciferol|1,25-DHCC preparation|1,25(OH)2D3 preparation|Product containing calcitriol (medicinal product)|1,25-Dihydroxyvitamin D3|Calcitriol|Calcitriol (substance)|1,25-Dihydroxycholecaliferol|1,25-Dihydroxycholecalciferol|1,25 Dihydroxycholecalciferol|Calcitriol preparation|1 alpha,25-Dihydroxyvitamin D3 preparation|1,25-dihydroxycholecalciferol|1,25 dihydroxycholecalciferol|1,25(OH)2-D3|(1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol|1 alpha,25-Dihydroxycholecalciferol|1,25-dihydroxyvitamin D3|1,25-DHCC|1,25 Dihydroxyvitamin D3|(5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol|Calcitriol-containing product|1α,25-dihydroxycholecalciferol|1-alpha-25-Dihydroxyvitamin D3|(1alpha,3beta,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol|CALTROL|D3, 1 alpha,25-Dihydroxyvitamin|1, 25-Dihydroxy cholecalciferol|1,25-diOHCC - 1,25-dihydroxycholecalciferol|calcitriol|CALCITRIOL|1α,25-dihydroxyvitamin D3|1,25-Dihydroxy cholecalciferol|1α,25(OH)2D3|(1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol|Calcitriolum|1 alpha,25-Dihydroxyvitamin D3|1,25-diOHC preparation | calcitriol |
C0025741 | An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent. | O methyl DOPA|methyldopa (levorotatory)|Methyldopa-containing product|AMD|alpha-Methyldopa|alpha-methyldopa|L-Tyrosine, 3-hydroxy-alpha-methyl-|L-alpha-Methyldopa|Methyldopa (substance)|Levo-3-(3,4-Dihydroxyphenyl)-2-methylalanine|(S)-(-)-alpha-Methyldopa|alpha-Methyl dopa|alpha-methyl-L-dopa|Alphamethyldopa|α-methyl-L-dopa|Product containing methyldopa (medicinal product)|METHYLDOPA|3-Hydroxy-alpha-methyl-L-tyrosine|L-2-Amino-2-methyl-3-(3,4-dihydroxyphenyl)propionic Acid|alpha-Methyl-L-Dopa|metildopa|alpha methyldopa|alpha Methyldopa|methyldopa|alpha Methyl L Dopa|Methyldopa|alphamethyldopa|Methyl dopa|α-Methyl dopa|L-Methyl Dopa|Alpha medopa | methyldopa |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.